Many recent studies have cast doubt on the utility of continuous antibiotics for children with reflux. The use of continuous antibiotics was previously thought to pre-vent bladder infections, and subsequent pyelonephritis and renal scars, in children with VUR. Several large prospective studies had demonstrated that antibiotics were as effective as operative intervention in preventing renal scars, although none of these studies included a control group managed without antibiotics (
4,
5). However, in 1997, Reddy randomly assigned a small group of children (n = 29) to treatments of daily antibiotics, no antibiotics, or antibiotics 3 times per week, and found no significant difference in the risk of urinary tract infection (UTI) or renal injury (
6). Subsequently, a retrospective study by Cooper et al. in 2000 demonstrated that 51 older children with VUR and normal voiding habits, as well as a minor history of UTIs, could be safely taken off antibiotics despite persistent VUR (
7). About 10% of these children developed recurrent UTIs, on average 2.3 years after the antibiotics were discontinued. Subsequent studies, both retrospective and prospective, confirmed that bowel and bladder dysfunction is a major risk factor for developing UTIs either on or off prophylaxis.
In 2001, Thompson demonstrated that a group of 196 children with VUR had the same rate of UTIs and new scar formation when on or off antibiotics (
8). Thus, this study also suggested that not all children with VUR benefit from daily antibiotics. However, in 2002, Hellerstein et al. demonstrated that children with grade 3 or greater VUR, as well as voiding dysfunction, had an increased risk of VUR when taken off antibiotics (
9). Other retrospective studies also demonstrated that children with grade 3 or greater VUR, as well as bowel or bladder dysfunction, had an increased risk of febrile UTIs (
10,
11). The rate of febrile UTIs was about 10%, and they occurred on average 17 months after antibiotics were stopped.
A series of more recent prospective studies have reinforced the conclusion that grade 3 or greater VUR is a risk factor for pyelonephritis and renal scaring in the absence of antibiotics, whereas antibiotics do not seem beneficial in cases of grade 2 or lower VUR. In 2006, Garin et al. demonstrated that 113 children with grades 1–3 VUR, who were randomized to receive or not receive antibiotics, showed no significant differences in susceptibility to UTIs or renal scars (
12). In fact, the highest percentage of patients with pyelonephritis in this study comprised those who had VUR and were on antibiotics. In 2008, Pennesi reported on 100 children under 30 months of age with grades 2–4 VUR, diagnosed after pyelonephritis, who were randomized to antibiotics or observation for 2 years, and then all observed without antibiotics for an additional 2 years (
13). There was no significant difference in the incidence of pyelonephritis on or off antibiotics (36% vs. 30%, respectively). Dimercaptosuccinic acid (DMSA) scans were noted to be worse in 10 patients, all of whom had grade 4 VUR, which suggests that higher grades of VUR do increase the risk of renal damage. Another prospective randomized trial of antibiotics versus observation in children with grades 1–3 VUR was reported by Roussey-Kesler in 2008 (
14). This study showed no overall difference in rates of recurrent UTI or febrile UTI with or without antibiotics. Of note, patients with grade 3 VUR did have a higher risk of recurrent UTI than those with grade 2 VUR (P < 0.01). A similar prospective study that year also demonstrated grade 3 VUR, as well as younger age, to be risk factors for recurrence (
15). Recently, the Swedish Reflux Study reported, in a series of papers, the 2-year outcomes of 1-year old children with grades 3 and 4 VUR who were randomized to antibiotic prophylaxis, observation, or endoscopic treatment with Deflux® (Oceana Therapeutics, Edison, NJ) (
16). Children were matched for gender, grade of VUR, history of UTIs, and renal defects as demonstrated by DMSA scan. Recurrent UTIs in this group of young children with highgrade reflux occurred most frequently amongst those under surveillance without treatment (
17). Fifty-seven percent of the surveillance group had a UTI, which occurred on average 96 days after the study began, whereas only 19% of those on antibiotics had a febrile UTI, and this occurred after 589 days on average. As anticipated, those receiving Deflux® injections had a higher resolution rate; however, the rate of recurrence of reflux within 1 year was 20%, which is similar to other reported rates of VUR recurrence following Deflux® (
18). Risk factors for febrile UTI included female gender and persistent VUR. Interestingly, renal damage at entry was not predictive of subsequent UTI or further renal damage (
19). Aside from those in the group under surveillance without antibiotics, other patients with increased risk of renal deterioration included those with bowel or bladder dysfunction, and, as expected, those who had febrile UTIs (
20). New renal damage was rare in boys.
It is useful to summarize what we have learned from the retrospective and prospective studies reviewed above. Antibiotic prophylaxis appears to provide little benefit for those with grade 2 or lower VUR. Conversely, antibiotic prophylaxis does appear to be beneficial for those with grade 3 or higher VUR, at least among girls. It can also be anticipated that about 15% of children with VUR will have a recurrent febrile UTI within 2 years, and about 15% of these children will develop a renal scar (
21). Bowel and/or bladder dysfunction (BBD) is a major risk factor for recurrent UTIs on or off antibiotics, which will occur in about 45% of children with BBD, as opposed to 15% of those without BBD (
3). Finally, it is important to remember that a higher grade of VUR is associated with an increased risk of both pyelonephritis and new renal damage (
22). The effect of age on the risk of renal damage is not well defined, although many believe that younger children are more susceptible to renal damage from pyelonephritis.
Aside from the questionable efficacy of antibiotic prophylaxis in children with low-grade reflux, there is growing concern about side effects. The most common concern with antibiotic use is the development of resistance.
Multiple studies confirm that exposure to antibiotics increases the likelihood that any subsequent UTIs will be caused by bacteria resistant to the previously prescribed antibiotics (
11,
17,
23-
25). In general, the risk of resistance appears to be about 3 times greater following treatment with antibiotics.